Sandoz Strikes $500m Deal For GSK Cephalosporins
Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
